,,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['trastuzumab', 'destiny,breast,03', 'breast', 't-dxd', 'trastuzumab deruxtecan', 'mbc', 'destiny-breast03']
top abstract trastuzumab deruxtecan (t-dxd) versus trastuzumab emtansine (t-dm1) in patients (pts) with her2-positive (her2+) unresectable and/or metastatic breast cancer (mbc): safety follow-up of the randomized, phase 3 study destiny-breast03 #asco22 
Vivek Subbiah, MD, (@VivekSubbiah) #PrecisionMedicine Expert and Medical Oncologist, takes over our Twitter today to discuss #ASCO22.